



Intravenous news: The FDA report “Hospira and FDA notified healthcare professional of a nationwide voluntary recall of one lot of Hydromorphone Injection, USP, 2 mg/mL, (C-II), 1 mL fill in 2.5 mL Carpuject, NDC 0409-1312-30, due to a reported complaint of a single Carpuject containing more than the 1 mL labeled fill volume. Opioid pain medications such as Hydromorphone have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), low blood pressure and reduced heart rate including circulatory collapse.”

[Click here for the full safety alert.](#)



Hospira hydromorphone hydrochloride injection product recall: May contain more than the intended fill volume | 2



Hospira hydromorphone hydrochloride injection product recall: May contain more than the intended fill volume | 3

